Indefinite Delivery Contract SPE2DU25D9390

The Department of Defense (DoD) awarded an Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, to provide a comprehensive range of pharmaceutical products and medical supplies to military healthcare facilities and veterans' medical centers nationwide. The single-award IDC, valued at $499,999,999 and valid through November 2026, enables the Defense Logistics Agency (DLA) to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables.

The contract supports the recurring medical supply needs of the DoD, including specialized medications such as Xolair, Trikafta, Keytruda, Botox, and Nucala, as well as various other pharmaceutical products and medical supplies. The contract is not associated with any set-aside designations, allowing DMS Pharmaceutical Group to leverage its status as a woman-owned small business to secure direct federal awards across multiple product categories and medical domains. The contract aims to ensure the DoD's resiliency and access to vital pharmaceuticals during times of contingency or natural disasters by diversifying the pharmaceutical supply chain through multiple regional awards.